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Management of Anthracycline Extravasation Injuries
David Reeves

Abstract
OBJECTIVE: To review the evidence for the management of anthracycline extravasation and determine
the optimal treatment of such injuries.
DATA SOURCES: A search of MEDLINE (1966–February 2007) and International Pharmaceutical
Abstracts (1970–February 2007) was performed using the search terms anthracyclines and extravasation.
DATA SYNTHESIS: Extravasation of anthracyclines can have devastating effects. After infiltration of
these drugs into the interstitial tissue, damage may range from mild erythema and pain to severe tissue
necrosis. Many agents have been studied in the management of these injuries; however, few have
demonstrated efficacy and treatment remains controversial. Nonpharmacologic modalities shown to limit
extravasation injuries include local tissue cooling and elevation of the affected area. Corticosteroids,
sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, α-tocopherol, N-acetylcysteine,
and granulocyte macrophage-colony stimulating factor have all either been shown to be ineffective or
have limited data supporting their use. Topical dimethyl sulfoxide (DMSO) has been shown in
prospective studies to limit the course of extravasation injuries. Dexrazoxane has been shown in animal
models and case reports to be useful in the management of anthracycline extravasation. Two recent
prospective clinical trials examining intravenous dexrazoxane 1000 mg/m2 within 6 hours of
extravasation, 1000 mg/m2 24 hours after extravasation, and 500 mg/m2 48 hours after extravasation
injuries add to the data supporting the use of this agent in such injuries. Of the 54 patients enrolled,
surgery-requiring necrosis was avoided in 98.2%.
CONCLUSIONS: The optimal treatment of anthracycline extravasation includes local tissue cooling,
elevation of the afflicted extremity, dexrazoxane administration, and possibly topical DMSO. Many other
drugs have been investigated; however, due to a lack of data, they cannot be recommended for the
management of anthracycline extravasation.
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What is the optimal treatment for anthracycline extravasation?

Response
BACKGROUND
Extravasation is a devastating complication that can develop when a drug infiltrates the interstitial
tissue surrounding the blood vessel. It can occur with any intravenously administered drug;
however, damage caused by some chemotherapeutic agents is particularly serious. Injury due to
extravasation has been reported to be responsible for 0.5–6% of adverse effects related to
chemotherapy administration.1 Those particularly harmful when extravasated include the
anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), and treatment of such a
complication due to these agents remains controversial.
The severity of tissue damage due to anthracycline extravasation is proportional to the amount and
concentration of drug that has infiltrated the interstitial tissue.2,3 The extent of damage can range
from mild erythema, edema, and pain to severe tissue necrosis and ulceration involving underlying
structures such as the extensor tendons of the hand. Ulceration may not present for weeks, which
is consistent with the mechanism of tissue injury caused by anthracyclines. Once these agents
infiltrate the tissue, they complex with DNA as an extension of their antitumor mechanism of
action and cause cell death. After the dying cells lyse, the anthracyclines are released and are able
to interact with additional cells, leading to a vicious cycle of tissue damage.1–3 Doxorubicin has
been shown to be present in the area of extravasation for up to 5 months after the incident.4 This
prolonged retention leads to continuing damage and prolongs healing time.
Use of an antidote for such injuries would be ideal; however, evidence supporting any one method
of managing anthracycline extravasation is limited. This lack of evidence is due partly to the rarity
of occurrences, as well as the complicated, urgent nature of the injury, which makes it difficult to
investigate in large, prospective, randomized studies. Unlike anthracycline-induced
cardiomyopathy, literature addressing anthracycline extravasation management is limited to
animal studies, case reports, and small human studies. Some of the therapeutic modalities
investigated for the management of anthracycline extravasation include tissue cooling and
elevation of the affected area, surgical debridement and reconstruction, injected and topical
cortico-steroids, sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, αtocopherol, N-acetylcysteine, granulocyte macrophage-colony stimulating factor (GM-CSF),
dimethyl sulfoxide (DMSO), and dexrazoxane. The majority of human data in anthracycline
extravasation includes the use of DMSO and dexrazoxane (Table 1).5–13
LITERATURE REVIEW
A search of MEDLINE (1966—February 2007) and International Pharmaceutical Abstracts
(1970—February 2007) was performed using the search terms anthracyclines and extravasation.
Review articles, clinical trials, animal studies, and case reports were identified, and references of

these articles were reviewed for additional reports. Articles most pertinent to the treatment of
anthracy-cline extravasation are reviewed here.

To prevent anthracycline extravasation, drug administration through a central line, when possible,
and ensuring good blood return prior to administration are of utmost importance. Moreover, the
use of liposomal doxorubicin has been shown to cause only mild extravasation reactions. In a
report of 8 extravasations of liposomal doxorubicin, patients developed transient, mild irritation at
the infusion site that resolved after removal of the catheter, elevation of the extremity, and
application of ice.14 Nevertheless, the anthracycline infusion should be stopped at the first sign of
extravasation. Cooling the site has been studied and is advocated in the product labeling of
idarubicin15 and doxorubicin.16 In a series of 50 patients treated with intermittent ice for 3 days
after extravasation of an antitumor agent, only 12 (24%) required surgical intervention.17
Additionally, product labeling recommends elevation of the involved extremity.
Pharmacologic approaches to treatment of extravasation have demonstrated varying response
rates; many have fallen out of favor. Sodium bicarbonate administered locally to increase tissue
pH and therefore decrease pH-dependent interactions of anthracyclines with cell components has
been shown to be of no benefit. In fact, local administration of sodium bicarbonate itself is
associated with tissue damage.1,2 Likewise, the use of glucocorticoids have fallen out of favor due
to the relative absence of inflammatory mediators in the afflicted area.1–3
Additional agents have been studied; however, many have limited data supporting their use.
Hyaluronidase breaks down hyaluronic acid, allowing increased absorption of anthracyclines.18

Moreover, heparin fractions are believed to have beneficial effects in anthracycline extravasation
by binding anthracycline, inhibiting coagulation, and promoting the formation of new
vasculature.19 In rat models, those receiving both subcutaneous hyaluronidase and heparin
fractions had significantly smaller ulcers compared with controls.18,19 Hyperbaric oxygen has also
been studied in the management of anthracycline extravasation. Conflicting results from 2 animal
studies (1 showing potentiation of cytotoxicity; 1 showing beneficial effects) limit the use of this
treatment modality.4 N-acetylcysteine has been shown to be of no benefit in treating anthracycline
extravasations.1 GM-CSF has been shown to accelerate wound healing, promote cellular adhesion,
and cause fibroblasts to have a more differentiated state. However, few cases describing the
successful use of GM-CSF have been reported.10 Due to a lack of clinical trial data, use of these
agents cannot be recommended.
Successful outcomes have been noted with the use of topical DMSO. Case reports and prospective
studies demonstrate that this agent can limit the course of the tissue injury caused by anthracycline
extravasation.5–7,20–22 In these reports, use of a 90–99% topical DMSO solution was described. For
the treatment of anthracycline extravasation, DMSO is believed to work by acting as a free radical
scavenger and by increasing systemic absorption of the extravasated drug.1 In an early animal
study (mouse model) evaluating the combination of DMSO and vitamin E (tocopheryl salts) for
the treatment of doxorubicin extravasation, investigators found that DMSO plus vitamin E did not
reduce ulceration.21 Reports23,24 in other animals have been favorable; it is not understood why
there was a lack of response in this mouse model.21
A prospective study was conducted in patients with either doxorubicin or daunorubicin
extravasation.5 DMSO was applied topically and allowed to air dry. Median time to DMSO
application after extravasation was 25 minutes, and none of the patients developed ulcerations or
required surgery. Severe blistering did occur in one patient who had DMSO applied under a
bandage. In a similar prospective study of 144 patients who experienced extravasation with
doxorubicin, epirubicin, mitomycin, mitoxantrone, cisplatin, carboplatin, ifosfamide, or
fluorouracil, the effect of DMSO was investigated.6 Forty of the 68 patients who received
doxorubicin, epirubicin, or mitomycin had complete resolution of symptoms by the end of one
week. Mild local burning was associated with DMSO application in this study. In another
prospective study, the effects of DMSO in combination with α-tocopherol were investigated for
the treatment of extravasation after administration of an anthracycline or mitomycin.7 None of the
patients developed ulceration, and the only adverse effects noted were local skin irritation and
blisters in 2 patients. Based on the results of these studies, some clinicians recommend the use of
DMSO in conjunction with immediate cessation of anthracycline infusion and application of
ice.1,2,4
Dexrazoxane has a Food and Drug Administration (FDA)—approved indication for use in
reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration
to women with metastatic breast cancer. In addition, recent data support its potential role in the
treatment of anthracycline extravasation. After intravenous administration, dexrazoxane is
metabolized intracellularly to ADR-925, which binds free iron and removes iron from the iron—
doxorubicin complex, thereby preventing formation of free radicals.25 Interactions between

anthracyclines and topoisomerase are also inhibited by dexrazoxane preventing the DNA-cleaving
activity of these agents.25 Three animal studies have examined the use of dexrazoxane in mice.26–
28
In all 3 studies, injuries caused by subcutaneous anthracycline administration were reduced by
intraperitoneal or intravenous dexrazoxane.
In addition to the aforementioned animal studies, dexrazoxane use for the treatment of
extravasation was described in 7 patients (Table 1).8–12 Three patients had extravasation with
epirubicin and 4 with doxorubicin. Dosage schedules and other supportive therapies varied among
the cases. Overall, injury due to extravasation was limited by administration of dexrazoxane. Three
patients did not experience necrosis and 6 patients were able to avoid surgery.8,9,11,12 Adverse
reactions reported included pain during dexrazoxane infusion, transient increases in results of liver
function tests, and leukopenia.9,11
Most recently, the results of 2 international studies were reported.13 Both were European
multicenter, open-label, single-arm trials. Patients (N = 17 and N = 36) were included if they had
developed anthracycline (ie, epirubicin, doxorubicin, or daunorubicin) extravasation proven by
fluorescence-positive tissue biopsy. The majority of patients were female, and the mean age was
55 years. Participants in both studies were allowed to receive localized cooling; topical treatment
with DMSO or steroids was not allowed. All patients received intravenous dexrazoxane 1000
mg/m2 within 6 hours after extravasation, 1000 mg/m2 24 hours after extravasation, and 500 mg/m2
48 hours after extravasation. The primary endpoint of both studies was prevention of surgeryrequiring necrosis.
All of the patients in the first study avoided surgery; one patient in the second study required
surgery. Additionally, 71% of the patients continued their scheduled chemotherapy regimen
without postponement. Overall, patients experienced only mild sequelae including sensory
disturbances, skin atrophy, pain, disfigurement, and limitation of movement. Toxicities with the
administration of dexrazoxane were mild. In the first study, 60.8% experienced injection site
reactions; after unspecified buffer changes in the second study, injection site reactions were
reduced to 14%. Wound infections, nausea, and vomiting occurred in 10.0%, 18.8%, and 7.5% of
the participants, respectively. Hematologic toxicities were demonstrated in this study; however, it
was unclear whether these were caused by the study drug or chemotherapy. Although these studies
were small, their results significantly add to existing data supporting the use of dexrazoxane in
anthracycline extravasation.13
Based on animal studies, case reports, and 2 prospective Phase II/III trials, dexrazoxane is a
promising agent for the treatment of anthracycline extravasation. Currently, dexrazoxane is
available in the US in 250- and 500-mg vials and is approved for prophylaxis of anthracyclineinduced cardiomyopathy. TopoTarget (Denmark) is seeking licensure of dexrazoxane for the
treatment of anthracycline extravasation and was granted orphan drug status by the FDA in 2004.
Doses used in the studies of dexrazoxane in anthracycline extravasation differ from those used in
the prevention of cardiomyopathy. For the prevention of cardiomyopathy, the drug is dosed in a
10:1 ratio (eg, dexrazoxane 500 mg/m2: doxorubicin 50 mg/m2). All doses reported in humans for
the treatment of anthracycline extravasation were fixed, ranging from 500 mg/m2 to 1500 mg/m2.

Adverse effects associated with the use of dexrazoxane in anthracycline extravasation were mild
in the 2 recently reported clinical trials and included injection site reactions, wound infections,
nausea, and vomiting.13 However, tissue necrosis was attributed to the use of dexrazoxane in one
case report in which the patient was receiving cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) in addition to dexrazoxane for the treatment of non-Hodgkin's lymphoma.29
During the dexrazoxane infusion, the patient experienced pain at the infusion site without evidence
of extravasation and subsequently developed tissue necrosis necessitating recurrent skin grafts.
Summary
Many agents have been investigated for use in anthracy-cline extravasation, yet results have not
shown effectiveness. Tissue cooling has been shown to be moderately effective and is
recommended in the product labeling of doxorubicin and idarubicin. Until recently, DMSO has
shown the most promising results in anthracycline extravasation. The latest agent to be
investigated, dexrazoxane, has shown efficacy in animal studies, case reports, and prospective
studies. Despite the limited nature of these reports, dexrazoxane appears to be a promising agent
for the treatment of anthracycline extravasation. Based on available literature, the optimal
treatment of anthracycline extravasation includes a combination of ice application, elevation of the
extremity, dexrazoxane administration, and possibly DMSO. Lack of evidence supporting use of
the additional agents discussed here limits their use.
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